Million A. Tegenge

734 total citations
32 papers, 482 citations indexed

About

Million A. Tegenge is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Million A. Tegenge has authored 32 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Immunology, 10 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Million A. Tegenge's work include CAR-T cell therapy research (7 papers), Biosimilars and Bioanalytical Methods (7 papers) and Pharmaceutical studies and practices (6 papers). Million A. Tegenge is often cited by papers focused on CAR-T cell therapy research (7 papers), Biosimilars and Bioanalytical Methods (7 papers) and Pharmaceutical studies and practices (6 papers). Million A. Tegenge collaborates with scholars based in United States and Thailand. Million A. Tegenge's co-authors include Iftekhar Mahmood, Hao Zhu, Robert J. Mitkus, Liang Zhao, Paul Seo, Rajanikanth Madabushi, Richard A. Forshee, Basil Golding, Issam Zineh and Yaning Wang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Clinical Infectious Diseases and Clinical Cancer Research.

In The Last Decade

Million A. Tegenge

30 papers receiving 462 citations

Peers

Countries citing papers authored by Million A. Tegenge

Since Specialization

Citations

This map shows the geographic impact of Million A. Tegenge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Million A. Tegenge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Million A. Tegenge more than expected).

Fields of papers citing papers by Million A. Tegenge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Million A. Tegenge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Million A. Tegenge. The network helps show where Million A. Tegenge may publish in the future.

Co-authorship network of co-authors of Million A. Tegenge

This figure shows the co-authorship network connecting the top 25 collaborators of Million A. Tegenge. A scholar is included among the top collaborators of Million A. Tegenge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Million A. Tegenge. Million A. Tegenge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti–PD-1–Based Immunotherapy 2025 ·Clinical Cancer Research ·(unknown), (unknown), Peter Bross, (unknown), (unknown), Karin M. Knudson, Million A. Tegenge, (unknown), Jamie R. Brewer, Marc R. Theoret, Lola A. Fashoyin‐Aje	1
2	Physiologically Based Pharmacokinetic Modeling and Simulation in Regulatory Review: US FDA CBER Experience and Perspectives 2025 ·The AAPS Journal ·Million A. Tegenge, Osman N. Yoğurtçu, Artur Belov, (unknown), Richard A. Forshee	0
3	Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1) 2023 ·International Immunopharmacology ·Million A. Tegenge, Iftekhar Mahmood, Evi Struble, Zuben E. Sauna	6
4	Pharmacokinetics of antibodies during Pregnancy: Impact of pregnancy on the pharmacokinetics of antibodies (Part 2) 2023 ·International Immunopharmacology ·Million A. Tegenge, Iftekhar Mahmood, Evi Struble, Zuben E. Sauna	1
5	Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta‐Analysis of Clinical Trials 2023 ·The Journal of Clinical Pharmacology ·Tingting Zhou, Million A. Tegenge, Basil Golding, John R. Scott	1
6	Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making 2022 ·Pharmaceutical Research ·Rajanikanth Madabushi, Paul Seo, Liang Zhao, Million A. Tegenge, Hao Zhu	102
7	Spreadsheet‐Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients 2021 ·The Journal of Clinical Pharmacology ·Iftekhar Mahmood, Million A. Tegenge	6
8	Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters 2021 ·Clinical Infectious Diseases ·Charles B. Stauft, Million A. Tegenge, Surender Khurana, Youri Lee, Prabhuanand Selvaraj, Hana Golding, Tony T. Wang, Basil Golding	6
9	Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction 2020 ·International Immunopharmacology ·Iftekhar Mahmood, Million A. Tegenge, Basil Golding	3
10	Population pharmacokinetics of immunoglobulin intravenous preparation in very low birth weight neonates 2020 ·International Immunopharmacology ·Million A. Tegenge, Iftekhar Mahmood	4
11	TCPRO: An In-Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity 2019 ·Biophysical Journal ·Osman N. Yoğurtçu, Zuben E. Sauna, Joseph R. McGill, Million A. Tegenge, Hong Yang	3
12	Comparative pharmacokinetic and biodistribution study of two distinct squalene-containing oil-in-water emulsion adjuvants in H5N1 influenza vaccines 2019 ·Regulatory Toxicology and Pharmacology ·Million A. Tegenge, Linda S. Von Tungeln, Steven A. Anderson, Robert J. Mitkus, Michelle M. Vanlandingham, Richard A. Forshee, Frederick A. Beland	12
13	TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity 2019 ·The AAPS Journal ·Osman N. Yoğurtçu, Zuben E. Sauna, Joseph R. McGill, Million A. Tegenge, Hong Yang	15
14	Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation 2019 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Yuching Yang, Xinyuan Zhang, Jeffry Florian, Hao Zhu, Million A. Tegenge, Shiew‐Mei Huang, Yaning Wang, Tina Morrison, Issam Zineh	112
15	Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations 2018 ·Regulatory Toxicology and Pharmacology ·Iftekhar Mahmood, Million A. Tegenge	2
16	A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents 2018 ·The Journal of Clinical Pharmacology ·Iftekhar Mahmood, Million A. Tegenge	39
17	Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance 2017 ·Clinical Pharmacokinetics ·Iftekhar Mahmood, Million A. Tegenge	5
18	Pharmacokinetics and biodistribution of squalene-containing emulsion adjuvant following intramuscular injection of H5N1 influenza vaccine in mice 2016 ·Regulatory Toxicology and Pharmacology ·Million A. Tegenge, Linda S. Von Tungeln, Robert J. Mitkus, Steven A. Anderson, Michelle M. Vanlandingham, Richard A. Forshee, Frederick A. Beland	18
19	A first-generation physiologically based pharmacokinetic (PBPK) model of alpha-tocopherol in human influenza vaccine adjuvant 2015 ·Regulatory Toxicology and Pharmacology ·Million A. Tegenge, Robert J. Mitkus	17
20	A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines 2013 ·Journal of Pharmacokinetics and Pharmacodynamics ·Million A. Tegenge, Robert J. Mitkus	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact